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Abstract 
Background. Patients with certain types of stroke need urgent anticoagulation and it is 
extremely important for them to achieve fast and stable anticoagulant effect and receive 
individualized treatment during the initiation of warfarin therapy. Methods. We conducted a 
prospective study among 210 acute stroke patients who had an indication for anticoagulation 
and compared the impact of CYP2C9 and VKORC1 genotype-guided warfarin dosing (PhG) 
with fixed dosing (NPhG) on anticoagulation control and clinical outcome between groups. 
Results. PhG achieved target INR values earlier, i.e. on average in 4.2 (4.1-4.7, 95%CI) days 
compared to NPhG [5.2 days (4.7-6.4, 95% CI)] (p=0.0009), spent a higher percentage of 
time in the therapeutic INR range [76.3% (74.7-78.5, 95% CI) versus 67.1% (64.5-69.6, 95% 
CI) in NPhG], and spent less time overdosed (INR>3.1) [PhG 0.4 (0.1-0.7, 95% CI), NPhG 
1.7 (1.1-2.3, 95% CI) days; p>0.000]. PhG reached stable maintenance dose faster [10 (9.9-
10.7, 95% CI) versus 13.9 (13.3-14.7, 95% CI) days in controls; p=0.0049] and had a better 
clinical outcome in relation to neurological deficit on admission as compared to NPhG. 
Conclusion. We confirmed that warfarin therapy with genotype-guided dosing instead of 
fixed dosing reduces the time required for stabilization and improves anticoagulant control 
with better clinical outcome in early stages of warfarin therapy introduction among acute 
stroke patients, which is essential for clinical practice. 
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INTRODUCTION  
 
Patients with cardioembolic stroke and stroke consequent to a specific condition (cerebral 
sinus venous thrombosis, dissection of intracranial arteries, hypercoagulable state) require 
urgent anticoagulation for secondary stroke prevention (1-4). This is important for prevention 
of arterial and venous thromboembolism, particularly of embolic stroke recurrences, and to 
reduce a high rate of in-hospital mortality in patients with recurrent embolism (19.6%) (5-6). 
Despite the emergence of new anticoagulants, warfarin is a widely prescribed first-line 
anticoagulant for most causes of embolic stoke due to its effectiveness in the management of 
thromboembolism and to its low cost (7-9).  
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Warfarin has narrow therapeutic index and at least 20-fold interpatient variations in dose 
requirements, which can lead to dose-related insufficient or excessive anticoagulation. Most 
dose-dependent adverse events emerge during introduction of therapy. Risk for hemorrhage or 
thromboembolism in this initiation period is higher than during later stages (event rates range 
from 16% to 25%) (10-11). Therefore, stroke patients that require anticoagulation are also at 
an increased risk of warfarin-dosage side effects and hence of recurrent stroke if they are 
underdosed or in overdosed conditions due to warfarin-induced brain hemorrhage (12-13). 
Warfarin pharmacogenetics, association of CYP2C9 and VKORC1 gene polymorphisms and 
dosing algorithms which use this genetic information are well documented (14-18).There are 
few studies available which have investigated the effectiveness of clinical application of 
genotype-guided dosing, and such studies conducted among acute stroke patients are 
specifically scarce (19-22). For these high-risk patients, it is essential to achieve stable 
anticoagulant effect as early as possible in order to prevent the risk of dosage-related 
complications by using the initial doses based on individual genotype (17, 23-24). The results 
of Franchini' s meta-analysis that included nine trials (2812 patients) show that genotype-
guided initial warfarin dosing significantly reduced the risk ratio for developing major 
bleeding events, compared with the control group (RR=0.47; P=0.04), or reduced serious 
bleeding events by approximately 50% compared to clinically-guided dosing group (25). Data 
obtained by meta-analysis of randomized clinical trials (Stergiopoulos et al.) indicated that a 
genotype-guided dosing strategy was not superior to clinical dosing algorithms in terms of 
INR values, reduction in major bleeding or thromboembolic events (26). 
Recently, several randomized controlled trials have been published with different conclusions 
on the clinical utility of genotype-guided dosing of coumarin anticoagulants. A study 
conducted by Pirmohamed group (EU-PACT trial) found that pharmacogenetic-based dosing 
was associated with a higher percentage of time in the therapeutic INR range than standard 
dosing during the initiation of warfarin therapy (27), while Kimmel group (COAG trial) did 
not confirm these findings for the anticoagulation period of the first 4 weeks of warfarin 
therapy (28). Also, Verhoef group did not confirm the findings for acenocoumarol or 
phenprocoumon during 12 weeks after the initiation of therapy in patients with atrial 
fibrillation or venous thromboembolism (29).  
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In this study, we compared the impact of CYP2C9 and VKORC1 genotype-guided dosing of 
warfarin with a standardized, fixed dosing regarding anticoagulation control and clinical 
outcome in acute stroke patients during the first three weeks of therapy.  
Patients and methods 
During six months, 587 Croatian Caucasian patients (EUCs) with acute ischemic stroke were 
hospitalized at the Department of Neurology, UHC Zagreb. We conducted a prospective trial 
among 210 (36% of the total number) patients with an indication for urgent anticoagulation, 
whose initial brain CT scan was without signs of hemorrhage. Detailed inclusion and 
exclusion criteria are listed in Table 1. 
Power analysis was done before the study. If the statistical significance level is set to p<0.05, 
and power to 0.95, two-tailed Fisher Exact test would need the sample size of n=96 in each 
group to detect the difference of at least 0.25 in proportion of patients with INR within the 
therapeutic range (2-3) at fifth day after the introduction of warfarin. Expected proportions 
were obtained in the pilot study done on the sample of n=20 patients. The proportion of 
patients with INR within therapeutic range (2-3) was 0.9 in PhG, and 0.4 in NPhG group. For 
more conservative calculation we set the expected proportions to 0.8 in PhG and 0.55 in 
NPhG group. Expecting approximately 5-10% of missing data the initial sample size was 
decided to be n=105 in each group. 
Eligible patients (N=210) were centrally registered and stratified according to gender and age, 
and then assigned to the intervention group [CYP2C9*2,*3 and VKORC11173C>T genotype-
guided dosing group, PhG (N=106)] or to the control/fixed dosing group (NPhG, N=104) 
(Figure 1).  
There were no differences between groups in gender (p=0.559), age (p=0.669) or indications 
for anticoagulation (inclusion criteria; p=0.591). Among the total number of 210 patients, 
32% were previously anticoagulated by using warfarin [34.9% (N=36) PhG and 28.8% 
(N=30) NPhG] and INR on admission was in all of them below the therapeutic range 
(INR<1.6). Atrial fibrillation was the most common indication for anticoagulation in both 
groups [56% of the total number; 53 (50.5%) in PhG, 65 (62.5%) in NPhG] (Table 2a). 
Since the number of eligible patients, i.e. those with appropriate diagnosis for our study 
(N=210) was relatively low and inclusion/exclusion criteria practically did not have any 
impact on patient selection as each patient required equal treatment and was consequently to 
be allocated in one of two study arms, we used a simple way of grouping (distribution) 
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patients by alternative allocation of every second patient into one of the two study arms.  
Moreover, having in mind that we could not influence patient's occurrence and patient's 
disease status in any manner, we considered that any possible bias was absolutely negligible, 
by using this method of allocation. 
Concomitant therapy and the number of smokers were similar in both groups. Once the 
ethical committee permission had been obtained, written informed consent form was provided 
for each PhG patient. 
Using non-profit website published algorithm http: //www.WarfarinDosing.org., we assessed 
initial pharmacogenetically-predicted warfarin dose, introducing a loading-dose strategy of 
warfarin for each patient in PhG during the first two to five days, while subsequently patients 
were treated on the basis of the INR (28-30). In the control group, warfarin was introduced by 
a fixed dose of 2 tablets of 3 mg warfarin (6 mg) for the first two to five days, and the doses 
were subsequently adjusted depending on the measured INR values. INR was measured 
repeatedly among patients where it was necessary, depending on previous INR values, and for 
the purposes of this study we recorded INR values on specific dates (INR at admission, on the 
first day of therapy introduction, at 48 hours, 72 hours, and days 5, 7, 14, and 21.) 
Blood samples (10 ml) were taken for INR measurement in both groups and for genotyping in 
PhG. The following data were recorded and compared between groups: indications for 
warfarin therapy, respective INR values depending on the day of warfarin introduction (as 
stated above), predicted dose (only PhG), dose of introduction, time to reach target INR ≥ 2, 
time/percentage of time spent in the therapeutic (2-3)/supratherapeutic (>3.1) INR values, 
time to reach a stable maintenance dose, dosage-dependent side effects and neurological 
deficit. A dose at which the patient was maintained within the therapeutic INR range and 
which did not change during three consecutive INR measurements for at least five days was 
defined as the stable maintenance dose.  
Warfarin dosage side effects and clinical outcome 
Warfarin-dosage side effects were classified into two groups. Group 1 included minor 
bleeding (asymptomatic microhematuria, slight gingival or vaginal bleeding, and 
subcutaneous hematoma). Group 2 included major bleeding which was classified into two 
subgroups: subgroup 2a) bleedings that did not require interruption of therapy, such as mild 
hemorrhagic transition of infarct zone without worsening of neurological deficit, and 
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subgroup 2b) bleedings that required interruption of warfarin therapy (large intracerebral 
hemorrhage with worsening of neurological deficit, extensive urogenital or gastrointestinal 
bleeding). Patients' neurological deficit on admission was estimated using the NIHSS scale 
(31). Clinical outcome defined as neurological deficit at the end of the study (follow-up 
period of three weeks) was assessed using mRS (32).  
 
Endpoints  
The primary endpoints to determine by comparing the PhG and NPhG were as follows:   
- time to achieve target INR≥2  
- proportion of patients who achieved the therapeutic INR 2-3 range depending on the 
day of measurement 
- time/percentage of time spent in the therapeutic/supratherapeutic INR range   
- clinical outcome   
- association of clinical outcome with the occurrence of dose-dependent side effects.   
 
The secondary endpoints were the following:  
- time needed to achieve a stable maintenance dose 
- proportion of patients who achieved a stable maintenance dose depending on the day 
of measurement 
- incidence of warfarin dosage-side effects.  
 
Genotyping procedures 
DNA was isolated from whole blood by salting out method. Three SNPs were genotyped by 
TaqMan® Drug Metabolism Genotyping Assays: CYP2C9*2 (rs1799853) with assay ID 
C_25625805_10, CYP2C9*3 (rs1057910) with assay ID C_27104892_10, and VKORC1 
1173C>T (rs 9934438) with assay ID C_30204875_10. The genotyping was performed by the 
Applied Biosystems 7500 Real Time PCR System according to the manufacturer's 
instructions (Applied Biosystems, Foster City, CA, USA). All assays were run in 96 well 
plates under the same instrument conditions: 2 min at 50°C, 10 min at 95°C, following 50 
cycles of 15 sec at 92°C with 90 sec at 60°C extension time. For each SNP, the 25 µl PCR 
reaction mixture per well consisted of 1.25 µl TaqMan® Drug Metabolism Genotyping Assay 
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Mix (specific for each polymorphism), 12.5 µl TaqMan® Universal PCR Master Mix and 5 -
20 ng of genomic DNA diluted in 11.25 µl dH20 (21, 33). 
 
Statistical Analysis 
The analysis was carried out by using the statistical software package STATISTICA ver. 6.0 
(StatSoft Inc., Tulsa, OK, USA). Quantitative variables were presented as an arithmetic mean 
(AM) and standard deviation (SD) when distribution was normal, otherwise as confidence 
interval (95% CI), median or interquartile range (IQR). 
Descriptive data were presented as frequency and proportion (such as time and percentage of 
time spent in therapeutic INR range). Student's t-test was used to compare the groups for 
quantitative variables (time required to achieve the target INR, time needed to achieve stable 
maintenance dose). χ2-test was used for comparison of descriptive variables. Analysis of 
variance (ANOVA) was used for comparison between the groups for quantitative variables 
depending on distribution. Results were considered statistically significant at the 5% level 
(p<0.05).  
 
Results 
Demographic and clinical data, as well as primary and secondary endpoint results are 
presented in Table 2a and Table 2b. 
Newly detected atrial fibrillation was the most frequent indication for warfarin therapy 
introduction (56.2% of patients). Before stroke, 32% of all included patients were receiving 
warfarin and on admission to hospital all of them had INR values below the therapeutic INR 
range (INR<1.6). The most common genotype among 36 underanticoagulated PhG patients, 
with the prevalence of 19.5% was “wild” homozygous CYP2C9 wt/wt, VKORC1 1173CC 
genotype.  
 
Primary endpoints  
The groups differed significantly in the time needed to reach the target INR≥2 and in the 
average INR values depending on the day of measurement (p=0.00017) (Table 2b; Figure 2.) 
PhG achieved INR≥2 earlier, i.e. on average in 4.4 (4.1-4.7, 95% CI) days as compared to 
NPhG [5.2 (4.7-6.4, 95% CI) days (p=0.0009)]. 
8 
 
On day 5, 63.2% of PhG entered the therapeutic INR range compared to 40.4% of NPhG 
(p=0.0026), on the seventh day 90.6% of PhG patients achieved the target INR compared to 
67.3% of NPhG (p=0.0005), and on the 14th day 99.1% of PhG patients achieved the 
therapeutic INR range compared to 80.8% of NPhG (p=0.0001). On the 21st day (at the end of 
the study), there were no differences between the groups (p=0.513).  
On the seventh day after warfarin introduction, supratherapeutic INR>3.1 was reached only 
by 6 (5.7%) PhG patients compared to 15.4% of NPhG patients, and on the 14th day by 1 
(0.9%) PhG patient compared to 16 (17.2%) NPhG patients who had INR>3.1. Finally, only 
9.3% of PhG patients achieved INR>3.1 in the monitored period, as opposed to 37.5% in 
NPhG [difference (control group minus genotype-guided group) 28.2 percentage points, 
p>0.000] (Table 3).  
PhG spent more time in the therapeutic INR range [16.1 (15.7-16.5, 95% CI) days or 76.6% 
(74.7-78.5, 95% CI) of time] as compared to NPhG [14.1 (13.6-14.6, 95% CI) days or 67.1% 
(64.5-69.6, 95% CI) of time] (p=0.0049) (Table 2b).  
PhG spent less time in supratherapeutic INR>3.1 range [0.4 (0.1-0.7, 95% CI) day] as 
compared to NPhG [1.7 (1.1-2.3, 95%CI) days] (p=0.000). 
Using the method of linear interpolation and Student's t-test, we confirmed differences 
between the PhG and NPhG in the time of entry into the target INR range (p=0.000), in the 
percentage of time spent in the therapeutic INR range (p=0.000), in the total time spent in the 
therapeutic INR range (p=0.000), as well as in the time spent outside the therapeutic INR 
range (p=0.000). We adjusted the doses and monitored clinical parameters, INR levels and 
brain CT findings in both groups if it was necessary, and found no differences between groups 
in the occurrence of warfarin-dosage side effects (χ2=0.688; df=2; p=0.7089). Side effects 
were observed in 16 (14.8%) of PhG patients, 7 (6.6%) had minor and 9 (8.3%) had major 
bleeding (Table 2a). Three patients in subgroup 2a had a discrete hemorrhagic transition of 
infarct zone without clinical deterioration. Warfarin side effects were observed in 18 (17.5%) 
NPhG patients, 10 (9.7%) patients had minor and 8 (7.8%) had major bleeding. In subgroup 
2a, three patients developed less severe hemorrhagisation of infarct zone without clinical 
worsening and three developed microhematuria, without discontinuation of the therapy. On 
the 19th day of therapy, one patient had extensive intracerebral hemorrhage with clinical 
deterioration and subsequent death (subgroup 2). The groups did not differ in the occurrence 
of warfarin-dosage side effects depending on the proportion of time in the therapeutic INR 
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range (p=0.560), although major bleeding in both groups occurred in those subjects who spent 
more time outside the therapeutic INR range.  
Neurological deficit on admission expressed by the NIHSS was 10.5 (SD5.00) for PhG and 
9.7 (SD 3.69) for NPhG. At the end of the study (a follow-up period of three weeks), residual 
neurological deficit (final clinical outcome) presented by mRS was 2.1 (SD 1.58) for PhG and 
2.4 (SD 1.36) for NPhG. By comparing the neurological deficit on admission and at the end 
of the study (using analysis of variance for repeated measurement), we found difference with 
better recovery in PhG (p=0.043) (Table 2a; Figure 3). 
We found no association of the final clinical outcome with the appearance of the dosage-
dependent side effects in PhG (p=0.1198), in contrast to the positive correlation in NPhG 
(p=0.0006). The association of clinical outcome with the appearance of complications was 
also confirmed by using Spearman correlation coefficients (rho=0.2617, p=0.0075). 
 
Secondary endpoint 
PhG achieved stable dose earlier, i. e. in 10 (9.9-10.7, 95% CI) days as compared to NPhG 
[13.9 (13.3-14.7, 95% CI) days] (p=0.0049). 
The groups differed in the proportion of patients who achieved stable maintenance dose 
depending on the time (p=0.000) (Figure 4). 
Within seven days of the therapy introduction, 9.4% of PhG subjects achieved stable dose but 
none from the NPhG. On the 10th day, cumulatively 59.5% of PhG subjects achieved stable 
dose as compared to 11.5% in NPhG. By the 12th day, a total of 94.3% of PhG subjects had 
stable maintenance dose as opposed to 39.4% of NPhG subjects. After two weeks, 97.1% of 
PhG and 60.5% of NPhG subjects achieved stable dose.  
 
Discussion 
Our investigation is the only study conducted exclusively among patients with acute stroke 
that need urgent anticoagulation, except for individual case reports and some studies of 
warfarin dosing formula among stroke patients in the available literature (21,23). Goals of our 
study were to determine whether pharmacogenetically-guided warfarin dosing could improve 
anticoagulation control and safety of warfarin treatment in comparison with standard, fixed 
dosing among stroke patients with indications for anticoagulation. The presented results 
confirm the value of implementing a pharmacogenetic algorithm that includes CYP2C9 *2,*3 
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and VKORC1 1173C> T gene polymorphisms in the prediction of the initial dose of warfarin. 
We found significant between-group differences, with earlier achievement of therapeutic INR 
levels and confirmed better anticoagulation control in PhG reported by the longer time spent 
in the therapeutic INR 2-3 range. Differences became apparent between the 5th and 14th day, 
with higher proportion of time spent in the therapeutic INR range and lower proportion of 
time spent in the supratherapeutic INR range, which is consistent with previously published 
data (27, 34-36) and highlights the importance of initiating warfarin therapy with a genotype-
guided dose in the early stage of the therapy introduction. When considering the impact of 
different parameters in warfarin dose prediction, it is important to be aware of MAFs (minor 
allele frequency) for VKORC1 and CYP2C9. Actually, studies of inter-ethnic differences in 
sensitivity to warfarin confirmed that the VKORC1 polymorphism had significantly greater 
influence on the variability of dose in Asians and Caucasians than in Afro-Americans. MAFs 
for VKORC1 -1639G>A in Asian, white, and black population were 0.91, 0.39, and 0.11, 
respectively. CYP2C9 variant allele frequencies are also rather variable among racial groups 
(4% in Asians, 5% in blacks, 20% in whites), which may explain some of the population-level 
differences in application of warfarin-dosing algorithms in racial groups (37-41).  
Our data differ from a study conducted among orthopedic patients in which authors did not 
find any differences in the anticoagulation control or in the incidence of complications 
between PhG and NPhG (19). In their study, 13% of patients had only CYP2C9 allelic 
variants, 44% of patients had VKORC1 polymorphisms, and 19% of patients had 
polymorphism for both genes, in contrast to our PhG group where polymorphism for only 
CYP2C9 gene was present in 32% of patients, 24.5% of patients had only the VKORC1 gene 
polymorphism, and 28.3% had polymorphism for both genes. This may contribute to 
differences of our results. In our study, serious complications were more frequent among 
carriers of VKORC1 1173C>T alleles (62.5%) and carriers of both defective CYP2C9*2 and 
*3 alleles (37.5%), but without significant difference between the genotypes.   
Secondary endpoints (stable anticoagulant effects) were also achieved in our study. Data 
confirmed that genotype-guided introduction reduced the time required for stabilization, i.e. 
PhG achieved a stable maintenance dose earlier, with greater proportion of stable 
anticoagulated patients depending on time as compared to NPhG. Our data demonstrated the 
difference between clinical outcome and the occurrence of complications between the two 
groups. We found no relations between the occurrence of warfarin-dosage side effects and the 
clinical outcome in PhG in contrast to positive correlation found in NPhG. This fact is 
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probably associated with the occurrence of more severe bleeding in the fixed-dosing group of 
patients. There is still no sufficient evidence to support the use of pharmacogenetics to 
prevent major complications and improve clinical outcome (39). The already mentioned 
different results obtained in several randomized controlled trials could be due to different 
approaches to dosing. EU-PACT trial applied fixed-dosing approach while clinical dosing 
algorithm was used in the COAG trial (27,28). Further, differences in the trial populations 
could have influence on study results, since additional variants discovered in African 
Americans could contribute to dose requirements (40,41).The strength of our study lies in 
investigation of a homogenous population of acute ischemic stroke patients among whom 
atrial fibrillation was the most frequent indication for warfarin therapy. In addition, the study 
was conducted in hospital settings where experienced cerebrovascular neurologists 
comprehensively monitored patients with ischemic stroke (42). Our data are consistent with 
the most recently published findings and remarks by Schwarz group (43). They found 
genotype-based dosing to be superior in patients who had atrial fibrillation as compared to 
patients who had venous thromboembolism, with the clear benefit when the participants 
harbored two or more variant alleles. This was the case in our study where homozygosity for 
"defective" variants of VKORC1 and CYP2C9 genes contributed to the earlier achievement of 
target INR and to the longest proportion of time spent within the therapeutic INR range in 
comparison to carriers of wild type alleles. This finding could be at least partly explained by 
the observation that “wild” type VKORC1 allele carriers can also be carriers of rare mutations 
and they require significantly higher doses, or can even develop resistance to warfarin. 
However, these mutations are not analyzed in routine clinical practice (44). 
We are aware that a limitation of this study is a relatively small number of enrolled patients 
and that our results need to be confirmed by further studies on larger populations of patients. 
Nevertheless, from the clinical point of view, we were able to detect clinically relevant 
differences. Our group of patients differed from respondents in other studies since they were 
in life-threatening condition due to the acute brain infarction, with an increased risk of 
bleeding and poor outcome due to the nature of the disease itself or because of warfarin-dose-
dependent over/under-anticoagulation. The risk of early embolic stroke recurrence range 
between 5-7% within the first week, with simultaneously increased risk of  hemorrhagic 
transformation of an ischemic infarct related to the nature of the ischemic brain damage and 
the risk of warfarin-induced brain hemorrhage due to overanticoagulation (45,46). Data from 
our study confirmed faster anticoagulant control and, bearing in mind that acute stroke 
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patients are at increased risk for recurrent embolism or warfarin-induced brain hemorrhage, 
we also confirmed safer anticoagulant control among them, with better clinical outcome and 
minor neurological deficit using genotype-guided warfarin dosing. This is important for the 
prevention of arterial and venous thromboembolism among acute stroke patients, particularly 
of embolic stroke recurrences.  
Conclusion  
Our study confirmed that initiating warfarin therapy with genotype-guided dosing has the 
greatest impact on anticoagulation control during the early stages of therapy introduction. 
This individualized treatment reduces the time required for stabilization, which is important 
for fast and stable anticoagulation in clinical practice, particularly among stroke patients who 
are at increased risk of brain hemorrhage caused by the nature of the disease itself. At the 
same time, they undergo a high risk of warfarin-dose dependent events, risk of stroke 
recurrence due to embolisms in underdosed conditions, or warfarin-induced brain hemorrhage 
in overdosed state. We confirmed better clinical outcome with minor neurological deficit 
using CYP2C9 and VKORC1 genotype-guided dosing compared to fixed warfarin dosing.  
 
Study Limitations 
A limitation of the study might be the size of observed patient groups. Randomisation and 
concealment of allocation are limitations, and could have biased the results. The lack of 
knowledge on control subjects' genotype could have had impact on the results. 
However, the obtained data indicated significant findings which need to be confirmed in 
replication studies and in other populations. 
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Table 1. Inclusion and exclusion criteria for the study 
 
 
Inclusion criteria  
1. Previously taking warfarin due to atrial fibrillation, 
mechanical heart valves, deep vein thrombosis, 
pulmonary embolism 
2. Newly discovered atrial fibrillation confirmed by 
HOLTER-ECG 
3. Acute dissection of intracranial arteries 
4. Patent foramen ovale with septal aneurysm 
5. Cerebral venous sinus thrombosis 
Exclusion criteria  
1. Age<18 year 
2. Hemorrhage in the brain, detected by CT scan, 
except in patients with cerebral venous thrombosis 
3. Malignancy, pregnancy 
4. Hepatic/renal insufficiency 
 
Table 2a. Demographic/ clinical data and some endpoint results among PhG/NPhG patients  
 
 
Patients  
Gender  
Age (year)  
Weight (kg) 
Height (cm) 
P A* 
nAF* 
ADA* 
PFO* 
VST* 
PhG (N=106) 
Female 60 (56%)  
67.6(SD 13.5) 
75.6(SD 10.3) 
171(SD 12.5) 
36(34.9%)  
53(50.5%) 
10(9.5%) 
3(2.9%)   
3(2.9%) 
NPhG (N=104)  
Female 62 (60%)  
69.1(SD 12.2) 
74.5(SD 10.6) 
172(SD 13.5) 
30(28.8%)  
65(62.5%) 
   5(4.8%) 
   2(1.9%)  
   2(1.9%)   
ND-a  NIHSS* 10.5(SD 5.00) 9.7(SD 3.69) 
ND-d  mRS*  2.1(SD 1.58) 2.4(SD 1.36) 
SE*  16(15.1%) 18(17.5%) 
SE mi 
SE ma 
7(6.6%) 
9(8.5%) 
10(9.7%) 
8(7.8%) 
 
N (number), PhG (pharmacogenetic-dosing group of patients), NPhG (fixed-dosing group of patients), 
SD (standard deviation); PA* (Previously anticoagulated); nAF* (Newly discovered atrial fibrillation 
confirmed by HOLTER-ECG); ADA* (Acute dissection of intracranial arteries); PFO* (Patent 
foramen ovale with septal aneurysm); VST* (Cerebral venous sinus thrombosis); ND-a NIHSS* 
(neurologic deficit at the admission expressed by NIHSS); ND-d mRS* (neurologic deficit at the end 
of the study, expressed by mRS); SE* (warfarin-dosage side effects); SE mi (warfarin-dosage side 
effects – minor bleeding); SE ma (warfarin-dosage side effects- major bleeding) 
Table 2b. Primary and secondary endpoints results among PhG/NPhG patients 
 
 
Patients  
 
PhG (N=106)  
95%CI 
NPhG (N=104)  
95%CI   
De  3.6-4.2 0 
Di  5.8-6.6 6.0 
Dm  3.4-4.0 3.6-4.5 
T-Dm*  10(9.9-10.7) 13.9(13.3-14.7) 
Tm*  16.1(15.7-16.4) 14.1(13.5-14.6) 
To*  0.0(0.07-0.7) 1.6(1.0-2.3) 
T %*  76.6(74.7-78.5) 67.0(64.5-69.5) 
T tg*  4.2(4.1-4.6) 5.2(4.7-6.3) 
 
N (number of PhG/NPhG patients); 95% CI (+/-95% confidence interval); De (estimated dose, mg); 
Di (dose of introduction, mg); Dm (stable maintenance dose, mg); T-Dm* (time needed to achieve 
stable maintenance dose, days); Tm* (time spent within the therapeutic INR range, days); To* (time 
spent within the INR>3.1, days); T %* (proportion of time within the therapeutic INR range); T tg* 
(time required to reach target INR values, days)  
Table 3. Frequencies of PhG and NPhG patients who achieved target INR ≥ 2, therapeutic 
INR 2-3, supratherapeutic INR>3.1 or INR>4, depending on the day of INR measurement 
 
 
Day of 
INR measur. 
N(%) PhG 
< targetINR 
N(%) PhG 
in target INR 2-3 
N(%) PhG 
INR>3.1 
N(%) PhG 
INR>4 
N(%) NPhG 
<target INR 
N(%) NPhG 
in target INR 2-3 
N(%) NPhG 
INR>3.1 
N(%) NPhG 
INR>4 
INR(3) 88(83.2) 18(16.98) 0 0 97(93.27) 7(6.73) 0 0 
INR(5) 36(33.96) 67(63.21) 0 3(2.83) 56(53.85) 42(40.38) 4(3.85) 2(1.92) 
INR(7) 4(3.77) 96(90.57) 5(4.72) 1(0.94) 18(17.31) 70(67.31) 14(13.46) 2(1.92) 
INR(14) 0 105(99.06) 0 1(0.94) 4(3.85) 84(80.77) 14(13.46) 2(1.92) 
INR(21) 2(1.89) 104(98.11) 0 0 1(0.96) 102(98.08) 1(0.96) 0 
 
N(%) PhG (number and percentage of pharmacogenetic-dosing group of patients); N(%) NPhG 
(number and percentage of fixed-dosing group of patients) 
  
Figure 1. Consort diagram 
Assessed for eligibility (587 Caucasian patients with acute ischemic stroke), grouped by 
allocation [eligible patients with an indication for urgent anticoagulation with warfarin that 
meets inclusion criteria, 36% (N=210) of total], PhG group (patients in pharmacogenetically-
guided group, N=106); NPhG group (patients without pharmacogenotypisation, fixed-dosing 
group, N=104) 
INR*Group; LS Means
Current effect: F(7, 1456)=4,1231, p=,00017
Effective hypothesis decomposition
Vertical bars denote 0,95 confidence intervals
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Figure 2. Time required to achieve the target International Normalized Ratio (INR)≥2 and the 
average INR values depending on the day of INR measurements and monitoring in PhG 
(pharmacogenetically-guided) and NPhG (fixed dosing) patients (p=0.0017) 
N.D.*Group; LS Means
Current effect: F(1, 208)=4,1448, p=,04303
Effective hypothesis decomposition
Vertical bars denote 0,95 confidence intervals
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Figure 3. Differences between the neurological deficit at admission (ND at admission, 
expressed by NIHSS) and neurological deficit at the end of the study (ND at discharge, 
expressed by mRS) between PHG (pharmacogenetic-dosing group) and NPHG (fixed-dosing 
group) (p=0.043) 
  
Figure 4. Frequencies of patients in pharmacogenetic-dosing group (PHG) and fixed-dosing 
group (NPHG), depending on the day of achieving stable maintenance dose (p=0.000)  
 
